Thursday, March 8, 2007

California Dairy Giant Rejects Hormone Treated Milk

Consumer groups and public health organizations give cheers to California’s dairy industry after the Associated Press, along with other news agencies, reported yesterday that members of the largest dairy cooperative in California will be required to supply milk that is free of the hormone RBST. California Dairies Company's 650 members produce approximately 40% of California's milk and 10% of the nation's. By August First, they'll have to stop injecting their herds with the genetically engineered hormone or pay a premium for the co-op to truck their milk to other markets.

The industry wide shockwaves expected will assist in bringing US production regulations closer to that of our trading partners. In Europe and Canada US dairy exports recently have faced increasing resistance because of the refusal by American producers to discontinue using the hormone. European and Canadian authorities banned the hormone, recognize RBST as a threat to human health and have linked it to cancer. Several years ago documents came to public attention that showed Monsanto lied about their studies in order to gain approval from the FDA. The evidence on this is stunning and I have included an exhaustive list of references and hope that everyone gives them at least a quick glance.[1-58]

The good news for the consumers and the cows is not in any case good news for Monsanto, they are going to lose billions of dollars. Monsanto is the only supplier of the hormone, sold under the name Posilac, and sales have been estimated at close to $300 million annually, although Monsanto refuses disclosure of actual figures. Monsanto Corporation, in case anyone has forgotten, is that esteemed member of the American corporate community that has brought us such wonders as Agent Orange, Roundup and is the world's leader in GMO's (genetically modified organism).

RBST or Posilac is also an excellent example of corporate welfare. Posilac causes cows to produce more milk. So... what is wrong with that you ask? American taxpayers pay farmers not to produce milk and have been doing so for years. [59] There is an excess of dairy products in this country and our government buys it using our money. They buy it to keep the prices stable. If the supply exceeds demand, the price of dairy drops. The government steps in and keeps product from reaching the market. It ends up in government warehouses where much of it is simply thrown away. This is where “government cheese” came from. What is not eaten by our poor, elderly, and native populations ends up in the trash. Do you think that Monsanto cares about the fact that their product is contributing to this? I think Monsanto sees the bottom line.

The trouble with this continues because not only has Posilac been recognized as a human health threat, but so is the milk it helps produce more of! Dairy proteins and fats have been linked to heart disease, stroke [60,6], cancer [62-66], diabetes (types 1&2) [67,68], multiple sclerosis, arthritis, Crohn’s disease, irritable bowl syndrome, fibromyalgia, osteoporosis [69-78], and more. So where did Monsanto get the bright idea for such a great product? Since great minds think alike, maybe it was a friend of one of Monsanto’s other top executives; Donald Rumsfeld was a CEO for Monsanto. Hmmmm.

My hat is off to the California dairy producers for standing up to Monsanto and their money grubbing schemes regardless of the reason. It is a rare day when I have anything positive to say about the dairy industry, today just happens to be one of them.


1. Conyers, John. Letter to Richard R. Kusserow, Inspector General, Department of
Health and Human Services. May 9, 1990.
2. Kennelly J & DeBoer G. Bovine somatotropin. In Proceedings of the Alberta Dairy Seminar. Banff, Alberta, March 9-11, 1998.
3. Baer RJ, et al. Composition and flavor of milk produced by cows injected with recombinant bovine somatotropin. Journal of Dairy Science 72:1424-1434, 1989.
4. Capuco, AV et al. Somatotropin increases thyroxine-5’-monodeiodinase activity in lactating mammary tissue of the cow. Journal of Endocrinology 121(2):205-211, 1989.
5. Epstein, SS. Potential public health hazards of biosynthetic milk hormones.
International Journal of Health Services 20:73-84, 1990.
6. Kronfeld, DS. Safety of bovine growth hormone. Science 251:256-257, 1991.
7. U.S. General Accounting Office. rBGH. FDA Approval Should Be Withheld Until the Mastitis Issues is Resolved. 1992.
8. Mepham TB. Public health implications of bovine somatotropin use in dairying: discussion paper. Journal of the Royal Society of Medicine 85:736-739, 1992.
9. Millstone E, et al. Plagiarism or protecting public health? Nature 371:647-648, 1994.
10. U.S. General Accounting Office. Recombinant bovine growth hormone. FDA approval should be withheld until the mastitis issue is resolved. 1992.
11. Davis SR, et al. Effects of injecting growth hormone of thyroxine on milk production and blood plasma concentrations of insulin-like growth factors I and II in dairy cows.
Journal of Endocrinology 114:17-24, 1987.
12. Prosser CG, et al. Changes in concentrations of IGF-1 in milk during BGH treatment in the goat. Journal of Endocrinology 112 (March Supplement): Abstract 65, 1987.
13. McBride BW, et al. The influence of bovine growth hormone (somatotropin) on animals and their products. Research and Development in Agriculture 5:1-21, 1988. page 5
14. Francis GL, et al. Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form. Biochem J. 251:95-103, 1988.
15. Prosser CG, et al. Increased secretion of insulin-like growth factor-1 into Milk of cows treated with recombinantly derived bovine growth hormones. Journal of Dairy Research 56:17-26, 1989.
16. Juskevich JC & Guyer CG. Bovine growth hormone food safety evaluation.
Science 249:875-884, 1990.
17. National Institutes of Health. Technology Assessment Conference Statement on
Bovine Somatotropin. Journal of the American Medical Association 265:1423-1425, 1991.
18. Joint FAO/WHO Expert Committee on Food Additives (JECFA). Fortieth Report,
Geneva. June 9-18, 1992. Cited six unpublished industry studies confirming increased IGF-1 levels in rBGH milk. These included one by Monsanto (Schams et al, 1988) reporting a four-fold increase, and another (Miller et al, 1989) reporting a further 50% increase following pasteurization.
19. Epstein SS. BST and cancer. New Scientist U.K., October 29, 1994.
20. Mepham TB, et al. Safety of milk from cows treated with bovine somatotropin.
The Lancet 2:197, 1994
21. Mepham TB & Schofield PN. International Dairy Federation Nutrition Week, Paris, June 1995.
22. Epstein SS. Unlabeled milk from cows treated with biosynthetic growth hormones:
a case of regulatory abdication. International Journal of Health Services 261:173-185, 1996.
23. Furlanetto RW & DiCarlo JN. Somatotropin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Research 44:2122-2128, 1984.
24. Glimm DR, et al. Effect of bovine somatotropin in the distribution of immunoreactive insulin-like growth factor-1 in lactating bovine mammary tissue.
Journal of Dairy Science 71:2923-2935, 1988.
25. Reynolds RK, et al. Regulation of epidermal growth factor and insulin-like growth factors I receptors by estradiol and progesterone in normal and neoplastic endometrial cells cultures. Gynecology Oncology 38:396-406, 1990. page 6
26. Lippman A. Growth factors, receptors and breast cancer. National Institutes of Health Research 3:59-62, 1991.
27. Rosen N, et al. Insulin-like growth factors in human breast cancer. Breast Cancer Research Treatment 18 (Suppl):555-562, 1991.
28. Harris JR, et al. Breast Cancer. New England Journal of Medicine 7:473-480, 1992.
29. Pollak MN, et al. Tamoxifen reduced insulin-like growth factor-1 (IGF-1). Breast Cancer Research Treatment 22:91-100, 1992.
30. Lippman ME. The development of biological therapies for breast cancer. Science 259:631-632, 1993.
31. Pappa V, et al. Insulin-like growth facotr-1 receptors are over expressed and predict a low risk in human breast cancer. Cancer Research 53:3736-3740, 1993.
32. Bruning PF, et al. Insulin-like growth factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. International Journal of Cancer 62(3):266-270, July 1995.
33. Epstein SS. Unlabeled milk from cows treated with biosynthetic growth hormones: a case of regulatory abdication. International Journal of Health Services 261:173-185, 1996.
34. LeRoith D. Insulin-like growth factors and cancer. Annals of Internal Medicine 122(1):54-59, January, 1995.
35. Bohlke K, et al. Insulin-like growth factor-1 in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9(5):570-573, 1998.
36. Del Giudice ME, et al. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Research and Treatment 47 (2):111-120, 1998.
37. Hankinson SE, et al. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. The Lancet 351:1393-1396, 1998.
38. Agurs-Collins T, et al. Insulin-like growth factor-1 and breast cancer risk in post-menopausal American women. Proceedings of the American Association of Cancer Research 40:152, 1999.
39. Toniolo P, et al. Serum insulin-like growth factor-1 and breast cancer.
International Journal of Cancer 88(5):828-832, 2000.
40. Yu H & Rohan T. Role of the insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 92:1472-1484, 2000. page 7
41. Epstein SS. Re Role of the insulin-like growth factors in cancer development and progression. Journal of the National Cancer Institute 93(3):238, 2001.
42. Pines A, et al. Gastrointestinal tumors in acromegalic patients. Am J Gastroenterology 80:266-269, 1985.
43. Orme SM, et al. Cancer incidence and mortality in acromegaly: a retrospective cohort study. Journal of Endocrinology Supplement Number OC22, June 1996.
44. Epstein SS. Unlabeled milk from cows treated with biosynthetic growth hormones: a case of regulatory abdication. International Journal of Health Services 261:173-185, 1996.
45. Manousos O, et al. IGF-I and IGF-II in relation to colorectal cancer. International Journal of Cancer 83:15-17, 1999.
46. Ma J, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor-1 and IGF-1 binding protein-3. Journal of the National Cancer Institute 91:620-625, 1999.
47. Giovannucci E, et al. Plasma insulin-like growth factor-I and binding protein-3 and risk of colorectal cancer and adenoma in women. Proceedings of the American Association of Cancer Research 40:211, 1999.
48. Renehan AG, et al. Circulating insulin-like growth factor II and colorectal adenomas. Journal of Clinical Endocrinology & Metabolism 85(9):3402-3408, 2000.
49. Mantzoros CS, et al. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. British Journal of Cancer 76:1115-1118, 1997.
50. Chan JM, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566, 1998.
51. Wolk A, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. Journal of the National Cancer Institute 90:911-915, 1998.
52. Signorello LB, et al. Insulin-like growth factor-binding protein-1 and prostate cancer.
Journal of the National Cancer Institute 91:1965-1967, 1999.
53. Stattin P, et al. Plasma insulin-like growth factor-binding proteins, and prostate
cancer risk: a prospective study. Journal of the National Cancer Institute 92:1910-1917, 2000.
54. Harman SM, et al. Serum levels of insulin-like growth factor I (IGF-1), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.
Journal of Clinical Endocrinology & Metabolism 85(11):4258-4265, 2000. page 8
55. Juul A, et al. The ratio between serum levels of IGF-1 and the IGF binding protein decreases with age in healthy patients and is increased in acromegalic patients. Clinical Endocrinology 41:85-93, 1994.
56. Tremble JM & McGregor AM. In Treating Acromegaly, editor Wass p. 5-12.
Journal of Endocrinology Ltd., Bristol, England, 1994.
57. Resnicoff M, et al. The insulin-like growth factor-I receptor protects tumor cells from apoptosis in vivo. Cancer Research 55(11):2463-2469, June 1,1995.
58. Epstein SS. Re: role of the insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 93(3):238, 2001
59. Milk Pricing in the United States. By Alden C. Manchester and Don P. Blayney.
Market and Trade Economics Division, Economic Research Service, U.S. Department
of Agriculture. Agriculture Information Bulletin No. 761.

60. Pennington JAT. Bowes and Churches Food Values of Portions Commonly Used, 17th ed. New York: Lippincott, 1998.
61. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA. Can lifestyle changes reverse coronary heart disease? Lancet 1990;336:129-33.
62. Cramer DW, Harlow BL, Willet WC. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet 1989;2:66-71.
63. Outwater JL, Nicholson A, Barnard N. Dairy products and breast cancer: the IGF-1, estrogen, and bGH hypothesis. Medical Hypothesis 1997;48:453-61.
64. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 1998;279:563-5.
65. World Cancer Research Fund. Food, Nutrition, and the Prevention of Cancer: A Global Perspective. American Institute of Cancer Research. Washington, D.C.: 1997.
66. Cadogan J, Eastell R, Jones N, Barker ME. Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial. BMJ1997;315:1255-69.
67. Scott FW. Cow milk and insulin-dependent diabetes mellitus: is there a relationship? Am J Clin Nutr 1990;51:489-91.
68. Karjalainen J, Martin JM, Knip M, et al. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N Engl J Med 1992;327:302-7.
69. Feskanich D, Willet WC, Stampfer MJ, Colditz GA. Milk, dietary calcium, and bone fractures in women: a 12-year prospective study. Am J Public Health 1997;87:992-7.
70. Cumming RG, Klineberg RJ. Case-control study of risk factors for hip fractures in the elderly. Am J Epidemiol 1994;139:493-505.
71. Huang Z, Himes JH, McGovern PG. Nutrition and subsequent hip fracture risk among a national cohort of white women. Am J Epidemiol 1996;144:124-34.
72. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-73.
73. Finn SC. The skeleton crew: is calcium enough? J Women’s Health 1998;7(1):31-6.
74. Nordin CBE. Calcium and osteoporosis. Nutrition 1997;3(7/8):664-86.
75. Reid DM, New SA. Nutritional influences on bone mass. Proceed Nutr Soc 1997;56:977-87.
76. Tucker KL, Hannan MR, Chen H, Cupples LA, Wilson PWF, Kiel DP. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am J Clin Nutr 1999;69:727-36.
77. Prince R, Devine A, Dick I, et al. The effects of calcium supplementation (milk powder or tablets) and exercise on bone mineral density in postmenopausal women. J Bone Miner Res 1995;10:1068-75.
78. The Cornell-China-Oxford Project. The China Study- Dr. T .Colin Campbell 2006

No comments: